<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405977</url>
  </required_header>
  <id_info>
    <org_study_id>CER 05-055</org_study_id>
    <nct_id>NCT00405977</nct_id>
  </id_info>
  <brief_title>The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block</brief_title>
  <acronym>MagRoc</acronym>
  <official_title>The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block - A Randomised Electrophysiology Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether an optimized pre-treatment with intravenous&#xD;
      magnesium enhances the speed of onset of a standard intubation dose of rocuronium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous study pre-treatment with intravenous MgSO4 60 mg kg-1 was not shown to have any&#xD;
      impact on the onset of action of rocuronium [Kussmann et al, 1997]. Yet, in that study, MgSO4&#xD;
      was injected as a bolus after induction of anaesthesia, one minute only before the injection&#xD;
      of the neuromuscular blocking agent. We suppose that magnesium needs some time to penetrate&#xD;
      the neuromuscular endplate and to shift the Mg/Ca ratio in favor of magnesium. Thus, the&#xD;
      particular design of the previous study may explain why magnesium had no scope to enhance the&#xD;
      speed of onset of action of rocuronium.&#xD;
&#xD;
      The aim of our study is to investigate whether an optimised pre-treatment with magnesium&#xD;
      (short infusion rather than bolus injection; reasonable delay between administration of&#xD;
      magnesium and subsequent injection of the neuromuscular blocking agent) enhances the speed of&#xD;
      onset of a standard intubation dose of rocuronium.&#xD;
&#xD;
        1. Preanaesthetic preparation&#xD;
&#xD;
             -  Solid food and liquid intake will not be allowed for a minimum of six hours before&#xD;
                induction&#xD;
&#xD;
             -  Patients will be premedicated with 7.5 mg oral midazolam 45 min prior to induction&#xD;
&#xD;
             -  Standard monitoring will consist of: ECG, SaO2, ETCO2, non-invasive blood pressure,&#xD;
                rectal or oesophageal T°&#xD;
&#xD;
        2. Study drug administration&#xD;
&#xD;
             -  Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding&#xD;
                to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given with an&#xD;
                Infusomat during 15 minutes.&#xD;
&#xD;
        3. Induction and maintenance of anaesthesia&#xD;
&#xD;
             -  At the end of the study drug infusion, and after a preoxygenation period of three&#xD;
                minutes, anaesthesia will be induced with sufentanil 0.2µg kg-1 and propofol, using&#xD;
                a Target Controlled Infusion (TCI) system (Base Primea, Fresenius-Vial, Brezins,&#xD;
                France) and the pharmacokinetic model of Schnider et al [Schnider et al, 1999]. The&#xD;
                initial effect site concentration will be 4 µg ml-1.&#xD;
&#xD;
             -  Maintenance of anaesthesia will be with a propofol effect site&#xD;
&#xD;
        4. Neuromuscular monitoring&#xD;
&#xD;
             -  Neuromuscular function will be monitored using the TOF Watch® SX (NV Organon) and&#xD;
                TOF nerve stimulation. The guidelines for good clinical research practice in&#xD;
                pharmacodynamic studies of NMBAs will be followed.&#xD;
&#xD;
             -  The ulnar nerve is stimulated through surface electrodes, and the adductor pollicis&#xD;
                muscle response is measured.&#xD;
&#xD;
             -  After the stabilisation period, rocuronium 0.6 mg kg-1 (2 x ED95) will be injected&#xD;
                intravenously during 5 seconds.&#xD;
&#xD;
             -  The trachea will be intubated after a 95% depression of the first twitch&#xD;
&#xD;
      5.1. Neuromuscular measurements&#xD;
&#xD;
        -  Onset time = time from beginning of injection of rocuronium until a 95% depression of&#xD;
           the first twitch (T1).&#xD;
&#xD;
        -  Duration 25% = time from beginning of injection of rocuronium until 25% T1 recovery.&#xD;
&#xD;
        -  Recovery index T25-75 = time between 25% T1 recovery and 75% T1 recovery.&#xD;
&#xD;
        -  Clinical recovery T25 - 0.9 = time between 25% T1 recovery and TOF ratio (T1/T4) of 0.9&#xD;
           (corresponding to safe extubation condition).&#xD;
&#xD;
      5.2. Haemodynamics&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Heart rate These measurements will be done before (baseline), and at 5-minute intervals&#xD;
           during the study drug infusion. Before and immediately after tracheal intubation,&#xD;
           haemodynamic measurements will be repeated.&#xD;
&#xD;
      5.3. Adverse events, safety&#xD;
&#xD;
        -  Any minor adverse event (no need for intervention) or major adverse events will be&#xD;
           recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study whether a pre-treatment with MgSO4, 60 mg kg-1, administered as an intravenous infusion 15 minutes prior to induction enhances the speed of onset of a standard intubation dose of rocuronium</measure>
    <time_frame>1 to 5 minutes</time_frame>
    <description>Onset time ist the time in seconds from start of injection of rocuronium until 95% depression of the first twitch (T1) of the Train of four (TOF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study whether, and to what extent, pre-treatment with MgSO4 prolongs recovery characteristics of the neuromuscular block that is induced by rocuronium</measure>
    <time_frame>minutes to hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study possible haemodynamic effects of pre-treatment with MgSO4.</measure>
    <time_frame>hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Physiologic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiologic saline</intervention_name>
    <description>Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.</description>
    <arm_group_label>Physiologic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.</description>
    <arm_group_label>Magnesium sulphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anaesthesiology (ASA) status I or II&#xD;
&#xD;
          -  Adults, aged 18 years to 60 years&#xD;
&#xD;
          -  Scheduled for elective surgery lasting longer than 120 min without need for continuous&#xD;
             curarisation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of allergy or hypersensitivity to rocuronium&#xD;
&#xD;
          -  Neuromuscular disease&#xD;
&#xD;
          -  Preoperative medications known to influence neuromuscular function (for instance,&#xD;
             certain antibiotics and anticonvulsants)&#xD;
&#xD;
          -  Electrolyte abnormalities&#xD;
&#xD;
          -  Hepatic or renal insufficiency&#xD;
&#xD;
          -  Patients with a body mass index &lt;19 or &gt;28 kg m2&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Expected difficult intubation or mask ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph A Czarnetzki, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Geneva, Anesthesia Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Tramer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Geneva, Anesthesia Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Geneva, Anesthesia Department</name>
      <address>
        <city>Geneva</city>
        <state>Canton of Geneva</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study. Acta Anaesthesiol Scand. 2010 Mar;54(3):299-306. doi: 10.1111/j.1399-6576.2009.02160.x. Epub 2009 Nov 16.</citation>
    <PMID>19919585</PMID>
  </results_reference>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>September 15, 2011</last_update_submitted>
  <last_update_submitted_qc>September 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Christoph Czarnetzki</investigator_full_name>
    <investigator_title>Study Leader</investigator_title>
  </responsible_party>
  <keyword>Neuromuscular block</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Rocuronium</keyword>
  <keyword>Time course of action</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

